Casebia in CRISPR/Cas9 development deal

Casebia Therapeutics, the joint venture founded by German pharma Bayer and gene-editing start-up CRISPR Therapeutics, has announced an exclusive license agreement and research collaboration to explore new methods to treat and prevent autoimmune disease using CRISPR/Cas9 gene-edited regulatory T cells with Seattle Children’s Research Institute.

Over the course of the collaboration agreement, funding contributions to Seattle Children’s, one of the USA’s top pediatric research centers, could exceed $12 million.